Puma Biotechnology Stock Price - PBYI

7.01
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Puma Biotechnology Inc PBYI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.34 -4.63% 7.01 6.81 7.49 7.29 7.35 00:00:08
Bid Price Ask Price Spread Spread % News
6.50 7.20 0.70 9.72% 2 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
7,745 864,461 $ 7.11 $ 6,148,975 1,450,162 5.50 - 35.70
Last Trade Time Type Quantity Stock Price Currency
17:04:48 formt 41,966 $ 7.01 USD

Puma Biotechnology Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 275.50M 39.30M $ -113.58M -1.95 -2.68 34.48M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% 4.00 12.30%

more financials information »

Puma Biotechnology News

Loading Messages....

Latest PBYI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PBYI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week8.648.796.817.68895,809-1.63-18.87%
1 Month9.3410.975.507.871,314,282-2.33-24.95%
3 Months8.8015.005.5010.831,993,313-1.79-20.34%
6 Months10.1715.005.509.531,830,910-3.16-31.07%
1 Year35.1635.705.5011.521,529,741-28.15-80.06%
3 Years36.10136.905.5038.651,205,464-29.09-80.58%
5 Years31.25136.905.5038.511,185,484-24.24-77.57%

Puma Biotechnology Description

Puma Biotechnology is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Puma licenses the commercial rights to its current drug candidates. The company expects to augment its product pipeline by acquiring, through license or otherwise, additional drug candidates for research and development and potential commercialization. In evaluating potential drug candidates, Puma employs disciplined decision criteria favoring drug candidates that have undergone at least some clinical study.


Your Recent History
NASDAQ
PBYI
Puma Biote..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.